Evidence map›Paper›PMID 33592371›Full record

SynthesisDiabetes & metabolic syndrome

The association between COVID-19 and type 1 diabetes mellitus: A systematic review.

Mahmoud Nassar, Nso Nso, Bahaaeldin Baraka, Mostafa Alfishawy, Mahmoud Mohamed, Akwe Nyabera, Issac Sachmechi

Erratum issuedAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Sars-Cov-2 Infection in People with Type 1 Diabetes and Hospital Admission: An Analysis of Risk Factors for England.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article
  13. Type 1 Diabetes and COVID-19: A Literature Review and Possible Management.International journal of endocrinology and metabolism · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. COVID-19 and chronic fatigue syndrome: An endocrine perspective.Journal of clinical & translational endocrinology · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Mahmoud NassarDepartment of Medicine, Icahn School of Medicine at Mount Sinai/NYC H&H Queens, NY, USA. Electronic address: Mahmoud.Nassar@MountSinai.org.
Nso NsoDepartment of Medicine, Icahn School of Medicine at Mount Sinai/NYC H&H Queens, NY, USA. Electronic address: mcviali@yahoo.co.uk.
Bahaaeldin BarakaOncology Department, Southend University Hospital, Mid and South Essex NHS Foundation Trust, ESSEX, UK. Electronic address: bahaabaraka@gmail.com.
Mostafa AlfishawyInfectious Diseases Consultants and Academic Researchers of Egypt IDCARE, Cairo, Egypt. Electronic address: malfishawy@kasralainy.edu.eg.
Mahmoud MohamedDepartment of Medicine, Division of Nephrology, University of Tennessee Health Science Center, USA. Electronic address: Mmohame3@uthsc.edu.
Akwe NyaberaDepartment of Medicine, Icahn School of Medicine at Mount Sinai/NYC H&H Queens, NY, USA. Electronic address: anyabera1@gmail.com.
Issac SachmechiDivision of Endocrinology, Department of Medicine, Mount Sinai Services, Queens Hospital, Center, NY, USA. Electronic address: SACHMECI@nychhc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background/Aim: Various reports of the occurrence of type 1 diabetes mellitus (T1DM) in patients with COVID-19 have been published, denoting an association between both diseases. Therefore, we conducted this systematic review to summarize the prevalence of T1DM in COVID-19 patients and to identify the clinical presentations and outcomes in this patient population. MATERIALS AND

methodsUp to 10/27/2020, Medline, Embase, cochrane and google scholar databases were searched for original studies investigating the association between COVID-19 and T1DM. A manual search was conducted to identify missing studies. The quality of included studies was analyzed by the National Institute of Health (NIH) risk of bias tool. Outcomes included length of hospital stay, hospitalization, intensive care unit (ICU) admission, diabetic ketoacidosis (DKA), severe hypoglycemia, and death.

resultsFifteen studies were included in the qualitative analysis. Included studies reported data of both adult and pediatric patients. The prevalence of T1DM in COVID-19 patients ranged from 0.15% to 28.98%, while the rate of COVID-19 in patients with T1DM ranged from 0% to 16.67%. Dry cough, nausea, vomiting, fever and elevated blood glucose levels were the most commonly reported presentations. The investigated outcomes varied widely among studied populations.

conclusionsThe prevalence of T1DM in patients with COVID-19 ranged from 0.15% to 28.98%. The most common presentation of COVID-19 in patients with T1DM included fever, dry cough, nausea and vomiting, elevated blood glucose and diabetic ketoacidosis. The outcomes of COVID-19 in terms of length of hospital stay, hospitalization, ICU admission, DKA rate, and severe hypoglycemia were reported variably in included studies. Due to the heterogeneous study populations and the presence of many limitations, more studies are still warranted to reach a definitive conclusion.

Indexed as

Blood GlucoseCOVID-19Diabetes Mellitus, Type 1HumansLength of StayBlood GlucoseCOVID-19Diabetes mellitusNew onsetT1DM

Identifiers

PMID33592371
PMCPMC7872855

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.